Alzheimer's Disease: Gammagard Fails

From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of immunoglobulin (IG) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease. The Gammaglobulin Alzheimer's Partnership (GAP) study was conducted by Baxter in collaboration with the Alzheimer's Disease Cooperative Study (ADCS), a clinical trial consortium supported by the United States National Institute on Aging in the National Institutes of Health. Topline analyses from the randomized, double-blind, placebo-controlled, multi-center trial found that after 18 months of treatment, patients with mild to moderate Alzheimer's disease taking Baxter's IG treatment at either the 400 mg/kg or the 200 mg/kg dose did not demonstrate a statistically significant difference in the rate of cognitive decline as compared to placebo (mean 7.4 in the 400 mg/kg group, 8.9 in the 200 mg/kg group, and 8.4 in the placebo group). Results also did not indicate a statistically significant change in functional ability as compared to placebo (mean -11.4 in the 400 mg/kg group, -12.4 in the 200 mg/kg group, and -11.4 in the placebo group). Read the full press release here. === Additional discussion at the Alzheimer Research Forum website at this page: Gammagard...
Source: BrainBlog - Category: Neurologists Source Type: blogs

Related Links:

Front cover:Mature neurons in the healthy central nervous system are considered to be permanently post ‐mitotic cells. In several neurodegenerative diseases, however, ectopic neuronal cell cycle events are found associated with regions of neuronal death. In the paper by Zhu et al., the authors use abnormal neuronal cell cycle activity as a screen to test natural compounds derived from marine bacter ia for their potential in preventing it and thus acting as neuroprotective agents.Image content: This image shows cerebellar Purkinje cells in one ‐month old mouse model of ataxia‐telangiectasia, a neurodegenerative diseas...
Source: Journal of Neurochemistry - Category: Neuroscience Tags: Issue Cover Source Type: research
The $2.5 million project was among several okayed by the state Department of Health that will expand access to care in the region.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Publication date: May 2020Source: Biomedical Signal Processing and Control, Volume 59Author(s): B. Richhariya, M. Tanveer, A.H. Rashid, for the Alzheimer’s Disease Neuroimaging Initiative
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
The risk of suffering many of the most common age-related conditions is trending downwards over time, thanks to improvements in medical technology and public health, but the ever increasing size of the older segments of the population means that the incidence of those age-related conditions will nonetheless grow over time. Growth in the number of older people outweighs the reduced risk for any given individual, or at least this will be the case without much faster progress towards effective therapies than has taken place over the past few decades. This is of great concern for those who focus more on socioeconomics t...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
This study was therefore aimed to assess the in vitro bioactivities associated with the LP EO. The EO was separated by hydrodistillation from the aerial parts of LP plants and analyzed for its antioxidant, antimicrobial, anticholinesterase, and antilipase activities. GC-MS was used for phytochemical analysis. The chemical analysis of the EO composition revealed 25 constituents, of which carvacrol (65.27%) was the most abundant. EO exhibited strong antioxidant (IC50 0.16-0.18 μL/mL), antiacetylcholinesterase (IC50 0.9 μL/mL), antibutyrylcholinesterase (IC50 6.82 μL/mL), and antilipase (IC50 1.0...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
I was on KPCC (NPR) in Los Angeles, yesterday, to address the question "Should Patients Diagnosed With Alzheimer’s Or Dementia Be Able To Choose Assisted Suicide?" A recent op-ed in the L.A. Times titled, “My friend has dementia and wants to end her life. California’s assisted-suicide law excludes her,” shines a light on the complexities of expanding the state’s law beyond patients with a cancer diagnosis or terminal illness. The law, passed in 2015 and modeled after a 1997 Oregon statute, allows physicians to give lethal drugs to mentally competent adults when they’re faced wi...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
Source: Journal of Computational and Theoretical Nanoscience - Category: Nanotechnology Authors: Tags: research-article Source Type: research
Source: Clinical Interventions in Aging - Category: Geriatrics Tags: Clinical Interventions in Aging Source Type: research
Abstract LW-AFC is a new formula derived from the Liuwei Dihuang decoction, a classical traditional Chinese medicine prescription. Based on our research, LW-AFC is a promising drug for Alzheimer's disease (AD). The studies were conducted primarily in two typical AD mouse models: SAMP8 and APP/PS1 mice. The results showed that LW-AFC could improve many cognitive behaviors, such as spatial learning and memory ability, passive and active avoidance response, and object recognition memory capability. In addition, LW-AFC could also alleviate the AD-like pathology in animal models, such as neuron loss and Aβ deposit...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Accumulating epidemiological evidence supports that chronic exposure to ambient fine particular matters of
Source: Frontiers in Physiology - Category: Physiology Source Type: research
More News: Alzheimer's | Clinical Trials | Health | National Institutes of Health (NIH) | Neurologists | Partnerships | Statistics | Study | Websites